Quantitative susceptibility mapping of the midbrain in Parkinson's disease - Wikidata - awgldk - TriplyDB

Quantitative susceptibility mapping of the midbrain in Parkinson's disease

Quantitative susceptibility mapping of the midbrain in Parkinson's disease

http://www.wikidata.org/entity/Q37650486

about

Parkinson's Disease: The Mitochondria-Iron Link Utility of susceptibility-weighted imaging in Parkinson's disease and atypical Parkinsonian disorders Susceptibility tensor imaging (STI) of the brain.Automated segmentation of the substantia nigra, subthalamic nucleus and red nucleus in 7T data at young and old age.The clinical utility of QSM: disease diagnosis, medical management, and surgical planning.Biomonitorization of iron accumulation in the substantia nigra from Lewy body disease patients.Quantitative Susceptibility Mapping in Parkinson's Disease.Quantitative T1, T2, and T2* Mapping and Semi-Quantitative Neuromelanin-Sensitive Magnetic Resonance Imaging of the Human Midbrain.The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward.Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.Meta-analysis of brain iron levels of Parkinson's disease patients determined by postmortem and MRI measurements.New Insights into the Crosstalk between NMDARs and Iron: Implications for Understanding Pathology of Neurological Diseases.Microstructural Changes within the Basal Ganglia Differ between Parkinson Disease Subtypes.Imaging of nigrosome 1 in substantia nigra at 3T using multiecho susceptibility map-weighted imaging (SMWI).Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.Magnetic resonance imaging for the diagnosis of Parkinson's disease.Ex-vivo quantitative susceptibility mapping of human brain hemispheres.Diagnosis of Early-Stage Idiopathic Parkinson's Disease Using High-Resolution Quantitative Susceptibility Mapping Combined with Histogram Analysis in the Substantia Nigra at 3 T.Quantification of liver iron concentration using the apparent susceptibility of hepatic vessels.Significance and In Vivo Detection of Iron-Laden Microglia in White Matter Multiple Sclerosis Lesions.Non-Motor Symptom Burdens Are Not Associated with Iron Accumulation in Early Parkinson's Disease: a Quantitative Susceptibility Mapping Study.Nigrosome Imaging and Neuromelanin Sensitive MRI in Diagnostic Evaluation of Parkinsonism Can neuroimaging predict dementia in Parkinson's disease?

P2860

Q26746899-D925CFC8-C9D0-4452-86E0-CEE672ECAB9F Q28066787-062CD1D0-7F14-474E-90FF-D7E5E74F09E6 Q31085912-EA5D825B-1C2B-47DD-A443-7667594A6C80 Q31110984-EB96F227-3365-48B4-8CFD-3A601AE112B8 Q31146333-B40DB266-022E-4EE2-A6E5-0F95D9F0E0D1 Q33703477-14209784-C2EF-47E7-9545-3DB7A7ABDC61 Q36123740-C87267D8-D8DE-46F7-BB25-764A77F511C2 Q36171001-2D251F89-4E35-401C-9E28-18C249F22BEF Q36332532-24895361-6029-47C7-911C-C361BCC27174 Q36374541-E6B11918-4807-4083-BF34-382236CA0429 Q37402514-29BED7F2-566F-4B07-8A2C-ECE08554FABE Q37703489-5556A0B7-F416-4E8D-BF6E-8C913A5324C6 Q38592102-0DEA7B3A-91B7-4C28-ADE7-3FF3FFE027C7 Q39176899-4134B1FD-CA59-4492-8635-214BB4FCE1F6 Q39179797-D798F8BE-E413-4171-88C9-42C6A8131A38 Q39220904-B92BDB22-4291-4BA0-834E-D220BCD8E94F Q47231355-C31A584B-E80E-4896-A269-344CB34BD630 Q50043640-BC9AE8B6-A57D-4820-9EBB-610DA7676200 Q52575817-DDA23FD9-44B5-4616-9209-5C3A52417F23 Q52668328-E874B37E-8090-41C7-8D32-F0FFE1EF6D03 Q55064137-AB096286-3315-4183-886C-45ED363CFA58 Q58576300-84188C80-4EDE-41B5-81AA-0FC6FD21CDDC Q58696822-48525BB5-56AD-4A5C-8125-0CC7E1D1BDC2

P2860

Quantitative susceptibility mapping of the midbrain in Parkinson's disease

http://www.wikidata.org/entity/Q37650486

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 September 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Quantitative susceptibility mapping of the midbrain in Parkinson's disease

@en

Quantitative susceptibility mapping of the midbrain in Parkinson's disease.

@nl

type

label

Quantitative susceptibility mapping of the midbrain in Parkinson's disease

@en

Quantitative susceptibility mapping of the midbrain in Parkinson's disease.

@nl

prefLabel

Quantitative susceptibility mapping of the midbrain in Parkinson's disease

@en

Quantitative susceptibility mapping of the midbrain in Parkinson's disease.

@nl

P1433

Q37650486-DE00BBBC-F156-4C46-B9FB-4B4033ACCEEB

P1476

Q37650486-95335DA4-E58A-4B5F-ADED-34543F7AA36B

P2093

Q37650486-007C7B60-96C6-4B51-9603-81B0C1A1C229

Q37650486-12B01C8B-637B-4AFE-B7BA-C436E3583305

Q37650486-312A84F7-3A3E-4713-B17E-25F85174782B

Q37650486-5A90192E-87EF-4CE7-8D35-1AAA906AEED3

Q37650486-A7CAF403-D861-4053-8DDE-1B3C1225A2C3

Q37650486-AF93E4EA-B2BD-47E7-A672-3B59A2DB608B

Q37650486-E8610E83-C112-4051-B9B8-9488622240B4

P2860

Q37650486-0210055E-9BB1-4004-A716-668759EF602F

Q37650486-06BAF98F-1F0A-4537-982F-287CE55B1850

Q37650486-16BB0795-ADF2-496F-9ADC-6C7EEEADEA2B

Q37650486-1A853933-6B02-41D0-B3C9-FEA4C7664FE7

Q37650486-1D57EFBD-7E56-40AB-8B2B-46480479E860

Q37650486-2783D01E-D0D2-4B83-A1C6-A485362A5FEB

Q37650486-31FE84F2-5ABF-4682-8E3D-138205F12A41

Q37650486-35E4C5E9-0F2F-4A83-A421-38EF250E00B4

Q37650486-3CD18F7F-A8DD-4F03-AC2A-FC0760C221EF

Q37650486-561B6792-6647-4FA0-B8B4-F3DBE04A6E77

P304

Q37650486-CDA7C72A-FDB8-4AD3-AAC2-D69F0F53DD59

P31

Q37650486-C8333589-BA71-4D4F-9657-1A8E6EB2370A

P356

Q37650486-F7F533D8-DA19-4D39-B761-47369181D364

P407

Q37650486-61BDCDDA-6472-4590-A977-1BD2CA9F29EA

P433

Q37650486-DA0416BC-0B27-41E4-94B8-5A5E4A40D6BE

P478

Q37650486-71B058E1-7765-4516-BFAC-3284F32412D5

P50

Q37650486-301252F2-B1D9-4A0B-BEA7-A0295D118329

P577

Q37650486-AE24B205-3FF7-4897-A780-95BC3FC4B72C

P5875

Q37650486-94F4AFC4-854C-4EF8-B91D-79BC18A7E166

P698

Q37650486-DC9F0AD3-FB00-4AF2-B39C-29046A15AFEF

P921

Q37650486-6FE2FBA8-2EA8-4D3E-935A-35D55DDAE427

P932

Q37650486-72074FB7-3E1C-460E-BD76-96B2B4E29204

P356

P1433

Movement Disorders

P1476

Quantitative susceptibility mapping of the midbrain in Parkinson's disease

@en

P2093

Guangwei Du

http://www.w3.org/2001/XMLSchema#string

James Connor

http://www.w3.org/2001/XMLSchema#string

Lan Kong

http://www.w3.org/2001/XMLSchema#string

Mechelle M Lewis

http://www.w3.org/2001/XMLSchema#string

Richard B Mailman

http://www.w3.org/2001/XMLSchema#string

Tian Liu

http://www.w3.org/2001/XMLSchema#string

Yi Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

Iron, brain ageing and neurodegenerative disorders

Ageing and Parkinson's disease: substantia nigra regional selectivity

UPDRS activity of daily living score as a marker of Parkinson's disease progression.

Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up.

Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker.

The role of iron in brain ageing and neurodegenerative disorders.

Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study.

Imaging iron stores in the brain using magnetic resonance imaging.

Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.

P304

317-324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.26417

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281713433

http://www.w3.org/2001/XMLSchema#string

P698

26362242

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

5315570

http://www.w3.org/2001/XMLSchema#string